Lotte Saaby1, Tina Svenstrup Poulsen1, Axel Cosmus Pyndt Diederichsen1, Susanne Hosbond1, Torben Bjerregaard Larsen2, Henrik Schmidt3, Oke Gerke4, Jesper Hallas5, Kristian Thygesen6, Hans Mickley7. 1. Department of Cardiology, Odense University Hospital, Odense, Denmark. 2. Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. 3. Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark. 4. Department of Nuclear Medicine, Odense University Hospital and Centre of Health Economics Research, University of Southern Denmark, Odense, Denmark. 5. Department of Clinical Pharmacology, University of Southern Denmark, Odense, Denmark. 6. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. 7. Department of Cardiology, Odense University Hospital, Odense, Denmark. Electronic address: Hans.mickley@rsyd.dk.
Abstract
BACKGROUND: The classification of myocardial infarction into 5 types was introduced in 2007. The prognostic impact of this universal definition, with particular focus on type 2 myocardial infarction, has not been studied prospectively in unselected hospital patients. METHODS: During a 1-year period, all hospitalized patients having cardiac troponin I measured were considered. The diagnosis of a myocardial infarction was according to the universal definition, and specified criteria were used in the classification of type 2 myocardial infarction. Follow-up was at least 1 year, with mortality as the end point. RESULTS: A total of 3762 consecutive patients were studied, of whom 488 (13%) had a myocardial infarction. In 119 patients a type 2 myocardial infarction was diagnosed. After a median of 2.1 years (interquartile range, 1.6-2.5 years), 150 patients had died, with a mortality rate of 49% (58/119) in those with type 2 myocardial infarction and 26% (92/360) in those with type 1 myocardial infarction (P < .0001). In a multivariable Cox regression analysis the following variables were independently associated with mortality: current or prior smoker, high age, prior myocardial infarction, type 2 myocardial infarction, hypercholesterolemia, high p-creatinine, and diabetes mellitus. The multivariable-adjusted hazard ratio for type 2 myocardial infarction was 2.0 (95% confidence interval, 1.3-3.0). With shock as the only exception, mortality was independent of the triggering conditions leading to type 2 myocardial infarction. CONCLUSIONS: Mortality in patients with type 2 myocardial infarction is high, reaching approximately 50% after 2 years. Further descriptive and survival studies are needed to improve the scientific evidence on which treatment of type 2 myocardial infarction is based.
BACKGROUND: The classification of myocardial infarction into 5 types was introduced in 2007. The prognostic impact of this universal definition, with particular focus on type 2 myocardial infarction, has not been studied prospectively in unselected hospital patients. METHODS: During a 1-year period, all hospitalized patients having cardiac troponin I measured were considered. The diagnosis of a myocardial infarction was according to the universal definition, and specified criteria were used in the classification of type 2 myocardial infarction. Follow-up was at least 1 year, with mortality as the end point. RESULTS: A total of 3762 consecutive patients were studied, of whom 488 (13%) had a myocardial infarction. In 119 patients a type 2 myocardial infarction was diagnosed. After a median of 2.1 years (interquartile range, 1.6-2.5 years), 150 patients had died, with a mortality rate of 49% (58/119) in those with type 2 myocardial infarction and 26% (92/360) in those with type 1 myocardial infarction (P < .0001). In a multivariable Cox regression analysis the following variables were independently associated with mortality: current or prior smoker, high age, prior myocardial infarction, type 2 myocardial infarction, hypercholesterolemia, high p-creatinine, and diabetes mellitus. The multivariable-adjusted hazard ratio for type 2 myocardial infarction was 2.0 (95% confidence interval, 1.3-3.0). With shock as the only exception, mortality was independent of the triggering conditions leading to type 2 myocardial infarction. CONCLUSIONS: Mortality in patients with type 2 myocardial infarction is high, reaching approximately 50% after 2 years. Further descriptive and survival studies are needed to improve the scientific evidence on which treatment of type 2 myocardial infarction is based.
Authors: Kris G Vargas; Paul M Haller; Bernhard Jäger; Maximilian Tscharre; Ronald K Binder; Christian Mueller; Bertil Lindahl; Kurt Huber Journal: Clin Res Cardiol Date: 2018-12-07 Impact factor: 5.460
Authors: Dirk Westermann; Johannes Tobias Neumann; Nils Arne Sörensen; Stefan Blankenberg Journal: Nat Rev Cardiol Date: 2017-04-06 Impact factor: 32.419
Authors: Avinainder Singh; Ankur Gupta; Ersilia M DeFilippis; Arman Qamar; David W Biery; Zaid Almarzooq; Bradley Collins; Amber Fatima; Candace Jackson; Patrycja Galazka; Mattheus Ramsis; Daniel C Pipilas; Sanjay Divakaran; Mary Cawley; Jon Hainer; Josh Klein; Petr Jarolim; Khurram Nasir; James L Januzzi; Marcelo F Di Carli; Deepak L Bhatt; Ron Blankstein Journal: J Am Coll Cardiol Date: 2020-03-10 Impact factor: 24.094
Authors: Andrew P DeFilippis; Ilya Chernyavskiy; Alok R Amraotkar; Patrick J Trainor; Shalin Kothari; Imtiaz Ismail; Charles W Hargis; Frederick K Korley; Gregor Leibundgut; Sotirios Tsimikas; Shesh N Rai; Aruni Bhatnagar Journal: J Thromb Thrombolysis Date: 2016-07 Impact factor: 2.300
Authors: Nathaniel R Smilowitz; Matthew C Weiss; Rina Mauricio; Asha M Mahajan; Kaitlyn E Dugan; Arvind Devanabanda; Claudia Pulgarin; Eugenia Gianos; Binita Shah; Steven P Sedlis; Martha Radford; Harmony R Reynolds Journal: Int J Cardiol Date: 2016-05-13 Impact factor: 4.164
Authors: Alok Ravindra Amraotkar; David Day Song; Diana Otero; Patrick James Trainor; Imtiaz Ismail; Vallari Kothari; Ayesha Singh; Joseph B Moore; Shesh Nath Rai; Andrew Paul DeFilippis Journal: Clin Appl Thromb Hemost Date: 2016-12-21 Impact factor: 2.389
Authors: Christoph B Olivier; Hillary Mulder; William R Hiatt; W Schuyler Jones; F Gerry R Fowkes; Frank W Rockhold; Jeffrey S Berger; Iris Baumgartner; Peter Held; Brian G Katona; Lars Norgren; Juuso Blomster; Manesh R Patel; Kenneth W Mahaffey Journal: JAMA Cardiol Date: 2019-01-01 Impact factor: 14.676